Interactive Features

Quiz

Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC

07/25/2022

In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?

In the single-arm CHRYSALIS...

07/25/2022

Oncology

Quiz

Quiz: Does This Treatment for Patients With Brain Metastases Show High Efficacy?

03/10/2022

True or false: Osimertinib shows poor outcomes for asymptomatic brain metastases.

True or false: Osimertinib shows...

03/10/2022

Oncology

Test Your Knowledge

Quiz: Are Anti-EGF Vaccinations Effective for EGFR+ NSCLC?

02/14/2022

True or false: Anti-EGF vaccinations provide zero clinical benefit for EGFR+ NSCLC.

True or false: Anti-EGF...

02/14/2022

Oncology

Test Your Knowledge

Quiz: Does Ivonescimab Show Excellent Anti-Tumor Effects in NSCLC?

02/08/2022

True or false: Ivonescimab shows excellent anti-tumor effects in NSCLC.

True or false: Ivonescimab shows...

02/08/2022

Oncology

Test Your Knowledge

Quiz: Are EGFR-TKIs Viable With Chemo in Advanced NSCLC?

01/31/2022

True or false: EGFR-TKIs with chemo achieve clinical benefit in advanced NSCLC.

True or false: EGFR-TKIs with...

01/31/2022

Oncology

Test Your Knowledge

Quiz: Most EGFR+ Lung Cancer Mutations are Which of the Following?

01/28/2022

Almost all EGFR+ lung cancers are ________.

Almost all EGFR+ lung cancers...

01/28/2022

Oncology

Test Your Knowledge

Quiz: What is the Effect of Smoking History in EGFR-Mutated NSCLC?

09/13/2021

True or false: EGFR-mutant NSCLC mainly occurs in non-smoking patients, but most series report 10% of cases in current of previous smokers.

True or false: EGFR-mutant NSCLC...

09/13/2021

Oncology

Test Your Knowledge

Quiz: What is the Effect of Smoking History in EGFR-Mutated NSCLC?

09/13/2021

True or false: EGFR-mutant NSCLC mainly occurs in non-smoking patients, but most series report 10% of cases in current of previous smokers.

True or false: EGFR-mutant NSCLC...

09/13/2021

Oncology

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Are CAR T-Cells Active Against EGFR+ Hypopharyngeal Carcinoma?

08/17/2020

True or False: EGFR-CAR T-cells produce anti-tumor activity in EGFR-positive hypopharyngeal carcinoma.

True or False: EGFR-CAR T-cells...

08/17/2020

Oncology

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology